Evidence map›Paper›PMID 33573910›Full record

ReviewTrends in molecular medicine2021

Ubiquitous Chromatin Modifiers in Congenital Retinal Diseases: Implications for Disease Modeling and Regenerative Medicine.

Brian W Basinski, Daniel A Balikov, Michael Aksu, Qiang Li, Rajesh C Rao

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Retina regeneration: lessons from vertebrates.Oxford open neuroscience · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Brian W BasinskiDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Daniel A BalikovDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Michael AksuDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Qiang LiDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Rajesh C RaoDepartment of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA; A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor, MI, USA; Section of Ophthalmology, Surgery Service, Veterans Administration Ann Arbor Healthsystem, Ann Arbor, MI, USA. Electronic address: rajeshr@umich.edu.
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Molecular Determinants for WDR5-Driven Transcriptional Regulation at Lineage-Specifying Genes During RetinogenesisR01EY030989 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, RAJESH C. · 2020 to 2024
$2.2M
Training Program in Translational ResearchT32GM141840 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDREW P LIEBERMAN, Zaneta Nikolovska-Coleska · 2021 to 2026
$2.0M
Training Program in Translational ResearchT32GM113900 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIEBERMAN, ANDREW P, NIKOLOVSKA-COLESKA, ZANETA · 2016 to 2020
$991k
NCI NIH HHS P30 CA046592NEI NIH HHS R01 EY030989NIGMS NIH HHS T32 GM113900NIGMS NIH HHS T32 GM141840
6 · The paper itself

Abstract

Retinal congenital malformations known as microphthalmia, anophthalmia, and coloboma (MAC) are associated with alterations in genes encoding epigenetic proteins that modify chromatin. We review newly discovered functions of such chromatin modifiers in retinal development and discuss the role of epigenetics in MAC in humans and animal models. Further, we highlight how advances in epigenomic technologies provide foundational and regenerative medicine-related insights into blinding disorders. Combining knowledge of epigenetics and pluripotent stem cells (PSCs) is a promising avenue because epigenetic factors cooperate with eye field transcription factors (EFTFs) to direct PSC fate - a foundation for congenital retinal disease modeling and cell therapy.

Indexed as

Cell- and Tissue-Based TherapyTranscription FactorsAnimalsAnophthalmosBlindnessChromatinColobomaCongenital AbnormalitiesDisease Models, AnimalEpigenomicsHumansMicrophthalmosPluripotent Stem CellsRegenerative MedicineRetinaRetinal DiseasesChromatinTranscription Factorsblindnessdevelopmentepigeneticsretinastem cells

Identifiers

PMID33573910
PMCPMC8034778
OpenAlexW3126767976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.